Key result
Diabetes is associated with similar restenosis and outcomes after successful CTO PCI versus non-diabetics.
Why the study?
Diabetes mellitus and chronic total occlusions are associated with unfavorable outcomes after PCI, but comparative clinical and angiographic outcomes in the drug-eluting stent era were unclear.
Do diabetic patients have worse clinical and angiographic outcomes compared to non-diabetic patients after successful percutaneous coronary intervention for chronic total occlusions with drug-eluting stents?
Cohort (n=207)
Do diabetic patients have worse clinical and angiographic outcomes compared to non-diabetic patients after successful percutaneous coronary intervention for chronic total occlusions with drug-eluting stents?
Absolute Event Rate: 4% vs 10.6%
p-value: p=0.180
In the drug-eluting stent era, diabetic patients achieve comparable and favorable clinical and angiographic outcomes to non-diabetic patients following successful percutaneous revascularization of chronic total occlusions.
Supports comparable CTO PCI outcomes in diabetics; leaves open need for randomized confirmation before changing practice.
Diabetes mellitus and chronic total occlusions are associated with unfavorable outcome after percutaneous coronary intervention. We sought to assess the clinical and angiographic outcomes of diabetic and non-diabetic patients who underwent successful percutaneous revascularization of chronic total occlusions with drug-eluting stents. Baseline clinical and angiographic characteristics, procedural details, nine-month angiographic follow-up and clinical events at 12 months were compared between 75 diabetic and 132 non-diabetic patients included in a clinical trial that randomized successful recanalization of chronic total occlusions to receive sirolimus- or everolimus-eluting stents. In both diabetic and non-diabetic groups there was a favorable non-significantly different angiographic result at nine months, with low in-stent late loss (0.14±0.60 mm vs. 0.25±0.68 mm, p=0.305) and rates of binary restenosis (4.0% vs. 10.6%, p=0.180) and reocclusion (0.0% vs. 2.3%, p=0.334). During follow-up similar survival from death (97.3±1.9% vs. 99.2±0.8%, log-rank p=0.273), acute myocardial infarction (100.0±0.0% vs. 97.7±1.3%, log-rank p=0.192), target vessel revascularization (88.7±3.8% vs. 88.2±2.9%, log-rank p=0.899) and stent thrombosis (100.0±0.0% vs. 97.7±1.3%, log-rank p=0.192) was observed. Furthermore, the presence of more diffuse peripheral and coronary artery disease and higher frequency of calcified lesions in diabetic patients did not lead to significant differences in the approach (20.0% vs. 25.0% radial approach, p=0.413), strategy (6.7% vs. 3.8% retrograde strategy, p=0.353), total stent length (48.1±24.6 mm vs. 49.2±23.9 mm, p=0758) or contrast volume (261.3±116.4 ml vs. 297.4±135.9 ml, p=0.109) required for revascularization. In the drug-eluting stent era, diabetic and non-diabetic patients have comparable favorable clinical and angiographic outcomes after successful percutaneous revascularization of chronic total occlusions. A diabetes mellitus e as oclusões crónicas totais estão associadas a resultados desfavoráveis após intervenções coronárias percutâneas. Procurámos avaliar os resultados clínicos e angiográficos dos doentes diabéticos e não diabéticos que se submeteram a revascularização percutânea bem sucedida da oclusão crónica total com stents revestidos. Características clínicas e angiográficas de base, detalhes técnicos, seguimento angiográfico a 9 meses e eventos clínicos a 12 meses foram comparados entre 75 doentes diabéticos e 132 não diabéticos incluídos num estudo clínico que aleatorizou a recanalização bem sucedida da oclusão crónica total para receber o stent revestido com sirolimus ou com everolimus. Em ambos os grupos diabéticos e não diabéticos houve um resultado angiográfico deiferente favorável e não significativo aos 9 meses com baixa taxa de in-stent loss (0,14±0,60 mm versus 0,25±0,68 mm, p=0,305) e taxas de reestenose binária (4,0% versus 10,6%, p=0,180) e reoclusão (0,0% versus 2,3%, p=0,334). Durante o seguimento foi observada sobrevivência semelhante de morte (97,3±1,9% versus 99,2±0,8%, log-rank p=0,273), enfarte agudo do miocárdio (100,0±0,0% versus 97,7±1,3%, log-rank p=0,192), revascularização do vaso alvo (88,7±3,8% versus 88,2±2,9%, log-rank p=0,899), e trombólise de stent (100,0±0.0% versus 97,7±1,3%, log-rank p=0,192). Além disso, a presença de doença periférica mais difusa, de doença das artérias coronárias e frequência mais elevada de lesões calcificadas nos doentes diabéticos não implicou diferenças significativas na abordagem (abordagem radial 20,0 versus 25,0%, p=0,413), estratégia (estratégia retrógrada 6,7% versus 3,8%, p=0,353), comprimento total do stent (48,1±24,6 mm versus 49,2±23,9 mm, p=0,758) e volume de contraste (261,3±116,4 ml versus 297,4±135,9 ml, p=0,109), necessário para a revascularização. Na era dos stents revestidos, os doentes diabéticos e não diabéticos podem apresentar resultados clínicos e angiográficos comparáveis e favoráveis, após revascularização precutânea da oclusão crónica total.
No takes yet. Share an insight, caveat, or question.
Ruiz-García et al. (2015) conducted a cohort in Chronic total occlusions (n=207). Diabetes mellitus vs. Non-diabetic patients was evaluated on Binary restenosis at 9 months (p=0.180). Diabetes mellitus was associated with comparable outcomes to non-diabetics after successful PCI for chronic total occlusions, including similar 9-month binary restenosis (4.0% vs 10.6%, p=0.180).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: